Qmiiz-ODT (Meloxicam Orally Disintegrating Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 9, 2018 Category: Drugs & Pharmacology Source Type: news

Take two: Recro tries for second time to get FDA approval for its non-opioid pain medicine
Recro Pharma Inc. is getting another shot at getting its lead new drug candidate approved by the Food and Administration. In May, the FDA rejected the Malvern, Pa., specialty pharmaceutical company's new drug application for its experimental, non-opioid pain medicine called intravenous meloxicam. On Monday, Recro (NASDAQ: REH) announced the federal agency has set March 24, 2019, as the new target date for making a d ecision on the company's resubmitted application that it said addresses the concerns… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 8, 2018 Category: Health Management Authors: John George Source Type: news

Recro Pharma to resubmit application for non-opioid pain medicine
Recro Pharma Inc. said Tuesday it expects to resubmit its new drug application for its lead product candidate, a non-opioid pain medicine, by the end of this month. In May, the Food and Drug Administration rejected the Malvern specialty pharmaceutical company's application seeking approval to market intravenous meloxicam for the management of moderate-to-severe pain. In its response letter, the FDA said the data suggested that the analgesic effect of the the rapy did not meet the agency's expectations. In… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 4, 2018 Category: American Health Authors: John George Source Type: news

Recro Pharma shares plummet after FDA rejects non-opioid pain shot
(Reuters) - Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA rejects Recro Pharma new drug application for a non-opioid pain medicine
The Food and Drug Administration rejected a new drug application submitted by Recro Pharma for its new drug candidate, a non-opioid pain medicine. The action sent the Malvern specialty pharmaceutical company's stock plunging by more than 50 percent to $6.14 in pre-market trading. In the complete response letter the FDA sent to Recro Pharma (NASDAQ: REPH), the FDA said it is unable to approve the application for IV meloxicam in its current f orm. IV Meloxicam is an intravenous formulation of an oral… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 24, 2018 Category: American Health Authors: John George Source Type: news

Recro Pharma's non-opioid pain shot fails to get approval from FDA
(Reuters) - Recro Pharma's IV meloxicam, a non-opioid injection, did not get approval from the U.S. Food and Drug Administration because the agency said the drug's pain-relieving effect did not meet its expectations. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan acquires fast-acting, non-opioid painkiller
Mylan (NSDQ:MYL) acquired global development and marketing rights to a fast-acting, non-opioid pain relief drug formulated by Prayog Labs, the company announced today. The pharma giant is positioning the medication, Meloxicam, as a non-addictive treatment option for patients experiencing acute pain following dentistry procedures or following a surgery. Get the full story at our sister site, Drug Delivery Business News. The post Mylan acquires fast-acting, non-opioid painkiller appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Pain Management Pharmaceuticals Wall Street Beat Mylan Source Type: news

Pharmaceutical Startup, Bridge Therapeutics, Announces Tim Peara Will Be Joining the Company as the Director of Finance
BIRMINGHAM, Ala., March 14, 2018 -- (Healthcare Sales & Marketing Network) -- The innovative late development-stage pharmaceutical startup, Bridge Therapeutics® has announced Tim Peara will be joining its management team as the new Director of Finance... Biopharmaceuticals, Drug Delivery, Personnel Bridge Therapeutics, buprenorphine, meloxicam, sublingual (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2018 Category: Pharmaceuticals Source Type: news

Pharmaceutical Startup, Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as New Chief Operating Officer
BIRMINGHAM, Ala., Feb. 21, 2018 -- (Healthcare Sales & Marketing Network) -- The innovative late development-stage pharmaceutical startup, Bridge Therapeutics®, has named David H. Bergstrom, Ph.D. as its new Chief Operating Officer effective immediate... Biopharmaceuticals, Drug Delivery, Personnel Bridge Therapeutics, buprenorphine, meloxicam, sublingual (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2018 Category: Pharmaceuticals Source Type: news

Recro Pharma Announces Key Executive Promotions to the Financial Team
MALVERN, Pa., Jan. 03, 2018 -- (Healthcare Sales & Marketing Network) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced several... Biopharmaceuticals, Personnel Recro Pharma, Meloxicam, dexmedetomidine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 3, 2018 Category: Pharmaceuticals Source Type: news

Ibuprofen vs. Meloxicam (Mobic) for Pain
Title: Ibuprofen vs. Meloxicam (Mobic) for PainCategory: MedicationsCreated: 11/1/2017 12:00:00 AMLast Editorial Review: 11/1/2017 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - November 1, 2017 Category: Anesthesiology Source Type: news

Vivlodex (Meloxicam Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 3, 2017 Category: Drugs & Pharmacology Source Type: news

Recro Pharma Appoints Bryan Reasons to Its Board of Directors
MALVERN, Pa., March 06, 2017 -- (Healthcare Sales & Marketing Network) -- Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and other acute care settings, today announced the appointment of B... Biopharmaceuticals, Personnel Recro Pharma, meloxicam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 6, 2017 Category: Pharmaceuticals Source Type: news

Meloxicam Tablets (meloxicam ) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 12, 2017 Category: Drugs & Pharmacology Source Type: news

Recro Pharma Appoints Michael Celano as Chief Financial Officer
MALVERN, Pa., July 05, 2016 -- (Healthcare Sales & Marketing Network) -- Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment... Biopharmaceuticals, PersonnelRecro Pharma, Meloxicam, dexmedetomidine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2016 Category: Pharmaceuticals Source Type: news

Mobic (Meloxicam) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2016 Category: Drugs & Pharmacology Source Type: news

VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
Third Low-Dose SoluMatrix® NSAID from Iroko Now Available by Prescription PHILADELPHIA, Feb. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the scie... Biopharmaceuticals, Product LaunchIroko Pharmaceuticals, VIVLODEX, meloxicam, NSAID (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2016 Category: Pharmaceuticals Source Type: news

Recro Pharma Appoints Fred Graff as Chief Commercial Officer
MALVERN, Pa., Feb. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment... Biopharmaceuticals, PersonnelRecro Pharma, Meloxicam, dexmedetomidine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2016 Category: Pharmaceuticals Source Type: news

Recro Pharma begins dosing in Phase III trial of IV meloxicam to manage acute postoperative pain
US-based Recro Pharma has started a Phase III clinical trial of intravenous (IV) meloxicam (N1539) to treat acute postoperative pain in patients. (Source: Drug Development Technology)
Source: Drug Development Technology - February 2, 2016 Category: Pharmaceuticals Source Type: news

Vivlodex (Meloxicam Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 9, 2015 Category: Drugs & Pharmacology Source Type: news

Iroko Pharmaceuticals Receives FDA Approval For VIVLODEX - First Low Dose SoluMatrix Meloxicam For Osteoarthritis Pain
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced recently that the United States Food and Drug Administration (FDA) approved VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain in 5 mg and 10 mg doses administered once daily. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - October 26, 2015 Category: Pharmaceuticals Source Type: news

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX(TM) - First Low Dose SoluMatrix(R) Meloxicam for Osteoarthritis Pain
VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low Doses PHILADELPHIA, Oct. 23, 2015 -- (Healthcare Sales & Marketing Network) -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advan... Biopharmaceuticals, FDAIroko Pharmaceuticals, VIVLODEX, meloxicam, NSAID, osteoarthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 23, 2015 Category: Pharmaceuticals Source Type: news

Recro Pharma Acquires Certain Alkermes' Assets
Recro acquisition includes worldwide rights to IV/IM meloxicam and contract manufacturing facility in Gainesville, Georgia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 15, 2015 Category: Pharmaceuticals Source Type: news

Patent Issued for Research Related to Alleviating Pain in Cattle
A patent has been issued for research that alleviates pain in cattle suffering from lameness and following castration, dehorning. The patent covers administering meloxicam alone or administering a combination of meloxicam and gabapentin to help alleviate acute and chronic pain and improve the performance of cattle. Researchers found that combinations of meloxicam and gabapentin improved the welfare of cattle by reducing the severity of lameness. Meloxicam alone improved weight gain after dehorning and reduced the incidence of bovine respiratory disease after castration. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 27, 2014 Category: Science Source Type: news

SoluMatrix(R) Meloxicam Demonstrates Significant Efficacy at 30 Percent Lower Doses in the Treatment of Osteoarthritis
Phase 3 Data Presented at EULAR 2014 PHILADELPHIA--(Healthcare Sales & Marketing Network)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that sho... BiopharmaceuticalsIroko Pharmaceuticals, SoluMatrix, meloxicam, osteoarthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 12, 2014 Category: Pharmaceuticals Source Type: news

meloxicam, Mobic
Title: meloxicam, MobicCategory: MedicationsCreated: 11/8/2000 8:38:00 PMLast Editorial Review: 10/11/2013 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 11, 2013 Category: Rheumatology Source Type: news

meloxicam, Mobic
Title: meloxicam, MobicCategory: MedicationsCreated: 11/8/2000 8:38:00 PMLast Editorial Review: 10/11/2013 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 11, 2013 Category: Drugs & Pharmacology Source Type: news